Hematological Cancer News Articles Provided by Cancer Compass
|
|
07/20/2010 Gene Therapy Shows Promise With 'Bubble Boy' Disease Statewide skin cancer rates for blacks, Hispanics differ from U.S. trends Read more at this website... 07/01/2010 Study Data From National Institutes Of Health Provide New Insights Into Non-Hodgkin Lymphoma It has been estimated that 65,980 individuals were diagnosed with non-Hodgkin lymphoma (NHL) and 19,500 died from NHL in the United States in 2009. Although established risk factors such as immunodeficiency and viral infections may be responsible for a portion of the cases, the majority of NHL cases remain unexplained, investigators in the United States report. Read more at this website... 07/01/2010 Be An Open-minded Skeptic; Consider A Wide Array Of Integrative Medicine Choices Integrative medicine focuses on mind, body and spirit, combining today's cutting-edge treatments with nontraditional techniques and approaches. The June issue of Mayo Clinic Health Letter features an in-depth Special Report on this rapidly growing area of medicine, covering mind-body, energy and hands-on therapies. Read more at this website... 06/24/2010 Moffitt Cancer Center Describes Research In Multiple Myeloma New investigation results, 'Single agent lenalidomide in newly diagnosed multiple myeloma: a retrospective analysis,' are detailed in a study published in Leukemia & Lymphoma. According to a study from the United States, Recently, lenalidomide and low dose dexamethasone were found to result in superior overall survival compared to lenalidomide and high dose dexamethasone. Read more at this website... 06/24/2010 Control Of Cancer Cell Pathways Key To Halting Disease Spread, Stanford Study Shows Oncogenes are like friends who've gone off the deep end. Normally steady, reliable members of the cellular workforce, these genes become very bad influences when mutated or expressed at high levels -- urging a cell to divide uncontrollably and become cancerous. Read more at this website... 06/24/2010 Researchers' Work From Academic Medical Center, Department Of Hematology Focuses On Non-Hodgkin Lymphoma A report, 'Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study,' is newly published data in Journal of Clinical Oncology. Read more at this website... 06/24/2010 Research From University Of Texas, M. D. Anderson Cancer Center In The Area Of Hematology Published A report, 'CT-guided percutaneous lung biopsies in patients with haematologic malignancies and undiagnosed pulmonary lesions,' is newly published data in Hematological Oncology. According to recent research published in the journal Hematological Oncology, We searched the electronic patient database at The University of Texas M. D. Anderson Cancer Center for patients who underwent computed tomography (CT)-guided needle biopsy between January 2001 and December 2005. Read more at this website... 06/24/2010 Study Shows Hodgkin Lymphoma Survivors Lack Post-Treatment Screening For Other Cancers A population-based study of 2,071 Hodgkin lymphoma (HL) survivors over 15 years has discovered that while many survivors had multiple X-rays and CT scans years after treatment was finished, they often did not receive recommended cancer screening tests. Read more at this website... 07/15/2010 Tasigna Approval Widened to Include Early Stages of Rare Leukemia But users are at greater risk of heart disorder Read more at this website... 06/17/2010 Adding Novartis Drug Zometa To Chemotherapy Significantly Improved Overall Survival In Study Of Newly Diagnosed Multiple Myeloma Patients New data to be presented tomorrow at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL, show that the addition of Zometa (zoledronic acid) to first-line chemotherapy significantly improved overall survival for newly diagnosed multiple myeloma patients by 16% (P=0.0118) and progression-free survival by 12% (P=0.0179) compared with oral clodronate plus first-line chemotherapy. Read more at this website... 06/17/2010 Second-Line CML Drugs Evoke Faster, Better Front-Line Remissions Two drugs approved for treatment of drug- resistant chronic myeloid leukemia provide patients with quicker, better responses as a first therapy than the existing front-line medication, according to two studies published online by the New England Journal of Medicine. Read more at this website... 06/17/2010 New Hodgkin Disease Study Findings Reported From Lancaster University New research, 'The late effects of mantle field radiotherapy: the information and support needs of women survivors of Hodgkin's disease,' is the subject of a report. Researchers in Lancaster, the United Kingdom conducted a study To improve understanding of the information and support needs of women at risk from breast cancer after earlier treatment with mantle field radio therapy for Hodgkin's disease. Read more at this website... 06/17/2010 New Myeloma Drug Shows Promise In Early Testing A drug designed to target cancerous plasma cells appears promising in treating multiple myeloma, a type of blood cancer. A multi-center study looked at the drug elotuzumab, an antibody which is designed to target CS1, a protein on the surface of malignant plasma cells. Read more at this website... 06/17/2010 'Scout Scans' Map The Way In Non-Hodgkin's Lymphoma Treatment According to a study presented at SNM's 57th Annual Meeting, molecular imaging can evaluate and optimize non-Hodgkin's lymphoma therapy with Zevalin, a front-line radioimmunotherapy drug that uses a dose of radioactive material and mimics the body's own immune response to target and kill cancer cells while sparing nearby healthy tissues. Read more at this website... 06/17/2010 Government Moves To Oversee Genetic Tests Aimed At Consumers During a stay at a resort two years ago, Carol Arand purchased $4,000 in genetic tests after a spa physician praised their potential to improve her health. If ever she got sick, Arand reasoned, she could take the results to her doctor. I hoped that this genetic fingerprint could be useful, she said. Read more at this website... 06/17/2010 UF Oncologists fight Leukemia With Two-Pronged Therapy, Clinical Trials Planned A new therapy mounts a double-barreled attack on leukemia, targeting not just the cancer cells but also the environment in which those cells live and grow, University of Florida researchers report. Read more at this website... 06/17/2010 New Genomic Cancer Care Alliance Formed To Study Whole-Genome Sequencing In Cancer Treatment Life Technologies Corporation (NASDAQ: LIFE) announced the creation of the Genomic Cancer Care Alliance to help people battling cancer gain access to treatment options found through analysis of their genomic information. Founding partners include Fox Chase Cancer Center, Scripps Genomic Medicine, and the Translational Genomics Research Institute (TGen).The announcement came during the Consumer Genetics Conference being held June 2-4 in Boston. Read more at this website... 06/17/2010 Blood-Sugar Lowering Medications May Increase Risk For False Positive Results In Cancer Screenings A study presented at SNM's 57th Annual Meeting suggests that medication ingested to control blood-sugar levels can skew the results of cancer screenings using positron emission tomography (PET), a molecular imaging technique, by increasing absorption in the gut of the PET imaging agent called fluorodeoxyglucose (18F- FDG), which mimics sugar inside the body. Read more at this website... 06/11/2010 Many Hodgkin's Lymphoma Survivors Don't Get Post-Treatment Screening Patients who are treated for Hodgkin's lymphoma often don't get screened for other cancers in the years that follow, despite being at greater risk for certain cancers than the general population. Read more at this website... 06/11/2010 Phase III Study Showed First-Line Maintenance Use Of Rituxan Improved The Likelihood Of People With Follicular Lymphoma Living Without Their Disease Worsening Genentech, Inc., a wholly owned member of the Roche Group, and Biogen Idec announced data from the Phase III PRIMA study. The data showed that continuing Rituxan (rituximab) for two years in patients who responded to initial treatment with Rituxan plus chemotherapy, doubled the likelihood of them living without their disease worsening (progression-free survival or PFS) compared to those who stopped treatment (based on a hazard ratio of 0.50, 95% CI, 0.39; 0.64; p=Non-Hodgkin Lymphoma). Read more at this website... |
